The Types segmentation categorizes service offerings into capsid engineering, vector production, and analytical quality control. Capsid engineering services, encompassing serotype selection, peptide insertion, and immune‑evasion modifications, command premium fees due to their role in enhancing tropism and reducing pre‑existing immunity, thereby influencing a substantial share of high‑value contracts. Vector production services are subdivided into small‑scale GMP‑compliant batches for early‑phase clinical trials and large‑scale GMP runs for later‑phase or commercial supply, each with distinct cost structures and capacity requirements that together constitute the bulk of market revenue. Analytical quality control includes potency assays, genome integrity testing, and sterility assessments, essential for regulatory compliance and product release, adding a critical, though smaller, revenue layer. Collectively, these type‑based services shape the market taxonomy by aligning technical complexity and regulatory rigor with client spend, ensuring that each functional segment contributes uniquely to the overall market valuation.